Item Type | Name |
Academic Article
|
Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.
|
Academic Article
|
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
|
Academic Article
|
Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts.
|
Academic Article
|
Donor T cells to treat EBV-associated lymphoma.
|
Academic Article
|
Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease.
|
Academic Article
|
Epstein-Barr infection after bone marrow transplantation.
|
Academic Article
|
Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
|
Academic Article
|
EBV specific CTL: a model for immune therapy.
|
Academic Article
|
Immunotherapy for Epstein-Barr virus-associated cancers.
|
Academic Article
|
Gene and cell transfer for specific immunotherapy.
|
Academic Article
|
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.
|
Academic Article
|
Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.
|
Academic Article
|
Use of gene marking in bone marrow transplantation.
|
Academic Article
|
Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation.
|
Academic Article
|
Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines.
|
Academic Article
|
Preventing Epstein-Barr virus lymphoproliferative disease after bone marrow transplantation.
|
Academic Article
|
Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals.
|
Academic Article
|
Treatment of Epstein-Barr virus-associated malignancies with specific T cells.
|
Academic Article
|
Immunotherapy for Hodgkin's disease.
|
Academic Article
|
An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
|
Academic Article
|
Upper airway obstruction and pulmonary abnormalities due to lymphoproliferative disease following bone marrow transplantation in children.
|
Academic Article
|
The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients.
|
Academic Article
|
Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells.
|
Academic Article
|
A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
|
Academic Article
|
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation.
|
Academic Article
|
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.
|
Academic Article
|
Post-transplant lymphoproliferative disorders.
|
Academic Article
|
Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
|
Academic Article
|
Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients.
|
Academic Article
|
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses.
|
Academic Article
|
Immune therapy for EBV infections after hemopoietic stem-cell transplant.
|
Academic Article
|
Immunotherapy for Epstein-Barr virus-associated cancers in children.
|
Academic Article
|
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
|
Academic Article
|
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
|
Academic Article
|
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor.
|
Academic Article
|
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.
|
Academic Article
|
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.
|
Academic Article
|
Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.
|
Academic Article
|
Options for T-cell based therapies.
|
Academic Article
|
Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas.
|
Academic Article
|
Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease.
|
Academic Article
|
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.
|
Academic Article
|
Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation.
|
Academic Article
|
Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease.
|
Academic Article
|
Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor.
|
Academic Article
|
Commentary on journal of immunotherapy paper by melenhorst et al.
|
Academic Article
|
Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.
|
Academic Article
|
Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection.
|
Academic Article
|
Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections.
|
Academic Article
|
Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children.
|
Academic Article
|
Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma.
|
Academic Article
|
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs).
|
Academic Article
|
T cell therapies.
|
Academic Article
|
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.
|
Academic Article
|
Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation.
|
Academic Article
|
Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation.
|
Academic Article
|
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.
|
Academic Article
|
Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy.
|
Academic Article
|
Immunotherapy targeting EBV-expressing lymphoproliferative diseases.
|
Academic Article
|
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.
|
Academic Article
|
Gamma-interferon and tumor necrosis factor production after bone marrow transplantation is augmented by exposure to marrow fibroblasts infected with cytomegalovirus.
|
Academic Article
|
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506).
|
Academic Article
|
How I treat EBV lymphoproliferation.
|
Academic Article
|
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.
|
Academic Article
|
Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
|
Academic Article
|
Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation.
|
Academic Article
|
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.
|
Academic Article
|
Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.
|
Academic Article
|
Pharmacotherapy versus T lymphocytes for CMV.
|
Academic Article
|
Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.
|
Academic Article
|
Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.
|
Academic Article
|
Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity.
|
Academic Article
|
Adoptive immunotherapy for Epstein-Barr virus-related lymphoma.
|
Academic Article
|
Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.
|
Academic Article
|
Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease.
|
Academic Article
|
Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant.
|
Academic Article
|
Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease.
|
Academic Article
|
Prompt versus preemptive intervention for EBV lymphoproliferative disease.
|
Academic Article
|
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
|
Academic Article
|
Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab.
|
Academic Article
|
In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
|
Academic Article
|
Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
|
Academic Article
|
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.
|
Academic Article
|
Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.
|
Academic Article
|
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.
|
Academic Article
|
Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.
|
Academic Article
|
Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients.
|
Concept
|
Cytomegalovirus Infections
|
Concept
|
Herpesvirus 6, Human
|
Concept
|
Cytomegalovirus
|
Concept
|
Herpesvirus 4, Human
|
Concept
|
Herpesvirus 3, Human
|
Academic Article
|
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.
|
Academic Article
|
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.
|
Academic Article
|
Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.
|
Academic Article
|
T lymphocytes targeting native receptors.
|
Academic Article
|
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
|
Academic Article
|
Systemic inflammatory response syndrome after administration of unmodified T lymphocytes.
|
Academic Article
|
Reply to S. Yuan et al.
|
Academic Article
|
Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant.
|
Academic Article
|
Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.
|
Academic Article
|
CMV-specific T cells generated from na?ve T cells recognize atypical epitopes and may be protective in vivo.
|
Academic Article
|
Late-onset severe chronic active EBV in a patient for five years with mutations in STXBP2 (MUNC18-2) and PRF1 (perforin 1).
|
Academic Article
|
T cells for viral infections after allogeneic hematopoietic stem cell transplant.
|
Academic Article
|
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.
|
Academic Article
|
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
|
Academic Article
|
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.
|
Academic Article
|
Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium.
|
Grant
|
Anti-viral and antileukemic T-cell therapy as prophylaxis after HSCT
|
Academic Article
|
EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation.
|
Academic Article
|
T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy.
|
Academic Article
|
Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
|
Academic Article
|
"Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients.
|
Academic Article
|
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells.
|
Academic Article
|
Sensitizing Burkitt lymphoma to EBV-CTLs.
|
Academic Article
|
Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas.
|
Academic Article
|
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study.
|
Academic Article
|
Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders.
|
Academic Article
|
High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia.
|
Academic Article
|
Engineering T cells to suppress acute GVHD and?leukemia relapse after allogeneic hematopoietic stem cell transplantation.
|
Academic Article
|
Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting.
|
Academic Article
|
Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy.
|